New York – Biotech startup Carta Biosciences is betting that its human gene interaction mapping technology can help drug companies reduce inefficiencies in their drug discovery efforts and more quickly discover novel drug targets.
Carta uses a systems biology approach and artificial intelligence algorithms to model and analyze causal pathways in disease with an eye towards identifying therapies that can reverse these pathways. The company believes that its approach will ultimately cut in half the current time and cost of drug development using traditional approaches.